Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | CA12 | O43570 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 1/20 | 0.58 |
| ▸ | CA6 | P23280 | 1/20 | 0.58 |
| ▸ | CA7 | P43166 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.58 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 6/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL2882428 | 0.98 | ALDH1A1 (0.60) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Phthalic Acid SCHEMBL321766 | 0.88 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDHMGB1NAPRT | |
| Phthalic Acid SCHEMBL2420682 | 0.85 | ALDH1A1 (0.50) | KDM4EALDH1A1HPGDCA12CA1 | |
| Formaldehyde SCHEMBL1582461 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1829341 | 0.80 | ALDH1A1 (0.82) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Catechol SCHEMBL15986788 | 0.80 | LMNA (0.55) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL25288775 | 0.79 | ALDH1A1 (0.78) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL31332109 | 0.79 | ALDH1A1 (0.78) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1003308 | 0.79 | ALDH1A1 (0.78) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL15568422 | 0.79 | ALDH1A1 (0.78) | KDM4EALDH1A1HPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165095-B1 | AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE | VITREO RETINAL TECHNOLOGIES IN (US) | 2008-05-28 | — | — | EP | claimed |
| US-20050137124-A1 | Agents for intravitreal administration to treat or prevent disorders of the eye | VITREO-RETINAL TECHNOLOGIES, INC. A CALIFORNIA CORPORATION | 2005-06-23 | — | — | US | claimed |
| EP-1165095-A4 | AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE | VITREO RETINAL TECHNOLOGIES IN (US) | 2004-12-15 | — | — | EP | claimed |
| EP-1165095-A1 | AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE | Vitreo-Retinal Technologies, Inc. (US) | 2002-01-02 | — | — | EP | claimed |
| WO-2000051620-A1 | AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE | VITREO-RETINAL TECHNOLOGIES, INC. (US) | 2000-09-08 | — | — | WO | claimed |
| CN-101711737-A | Agents for intravitreal administration to treat or prevent disorders of the eye | VITREO RETINAL TECHNOLOGIES IN | 2010-05-26 | — | — | CN | disclosed |
| CN-101711737-A | Agents for intravitreal administration to treat or prevent disorders of the eye | VITREO RETINAL TECHNOLOGIES IN | 2010-05-26 | — | — | CN | disclosed |
| EP-1165095-B1 | AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE | VITREO RETINAL TECHNOLOGIES IN (US) | 2008-05-28 | — | — | EP | disclosed |
| EP-1165095-B1 | AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE | VITREO RETINAL TECHNOLOGIES IN (US) | 2008-05-28 | — | — | EP | disclosed |
| US-7008960-B1 | Agents for intravitreal administration to treat or prevent disorders of the eye | VITREO-RETINAL TECHNOLOGIES, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-7008960-B1 | Agents for intravitreal administration to treat or prevent disorders of the eye | VITREO-RETINAL TECHNOLOGIES, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050137124-A1 | Agents for intravitreal administration to treat or prevent disorders of the eye | VITREO-RETINAL TECHNOLOGIES, INC. A CALIFORNIA CORPORATION | 2005-06-23 | — | — | US | disclosed |
| CN-1377272-A | Intravitreally administered agent for treating or preventing ophthalmic diseases | VITREO RETINAL TECHNOLOGIES IN (US) | 2002-10-30 | — | — | CN | disclosed |
| CN-1377272-A | Intravitreally administered agent for treating or preventing ophthalmic diseases | VITREO RETINAL TECHNOLOGIES IN (US) | 2002-10-30 | — | — | CN | disclosed |
| US-6462071-B1 | UREA, THIOUREA AND/OR HYDROXYUREA WITH NONSTEROIDAL ANTIINFLAMMATORY AND ANTIMETABOLITE DRUGS; NONENZYMATIC DISSOLUTION OF HYALOID MEMBRANES; LIQUEFACTION OF VITREOUS HUMOR; PREVENTING ACCUMULATION NEAR RETINA | VITREO-RETINAL TECHNOLOGIES, INC. | 2002-10-08 | — | — | US | disclosed |
| US-6462071-B1 | UREA, THIOUREA AND/OR HYDROXYUREA WITH NONSTEROIDAL ANTIINFLAMMATORY AND ANTIMETABOLITE DRUGS; NONENZYMATIC DISSOLUTION OF HYALOID MEMBRANES; LIQUEFACTION OF VITREOUS HUMOR; PREVENTING ACCUMULATION NEAR RETINA | VITREO-RETINAL TECHNOLOGIES, INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1165095-A1 | AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE | Vitreo-Retinal Technologies, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1165095-A1 | AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE | Vitreo-Retinal Technologies, Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000051620-A1 | AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE | VITREO-RETINAL TECHNOLOGIES, INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051620-A1 | AGENTS FOR INTRAVITREAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE | VITREO-RETINAL TECHNOLOGIES, INC. (US) | 2000-09-08 | — | — | WO | disclosed |